
RTW Investments is a life sciences investment and innovation firm headquartered in New York, investing in biotech and medtech across the full lifecycle from company creation to venture capital, alternative financing, and public companies.
62% of their portfolio is in Biotech & Life Sciences. Deal activity decreased year-over-year (2 deals in the last 12 months vs 10 prior). Average disclosed round size is $134.1M (across 38 rounds with reported amounts).
Portfolio
34
Fund Size
—
Top Stage
Series B
Last 12 Mo
2
Team
Sabera Loughran
Partner Emeritus, Founding COO and CFO
Roderick Wong, MD
Managing Partner, Chief Investment Officer
Dan Glynn
Managing Director, Private Wealth
Lauren Cuje
Managing Director, New Ventures
Matthew Bieret, CPA
Managing Director, Finance
Mike Christman
Managing Director, Operations
Paul Lu, PhD
Managing Director, Head of Corporate Development
Portfolio Breakdown
Stage Distribution
Sector Distribution
Investment Activity
Portfolio
| Company | Round | Amount | Date |
|---|---|---|---|
| Series A | $50M | Mar 2026 | |
| CCorxel Pharmaceuticals Limited | Series D | $287M | Jan 2026 |
| Series B | $120M | Jan 2026 | |
| Series A | $50M | Jan 2026 | |
| Growth | $200M | Jun 2025 | |
| Series C | $100M | Jan 2025 | |
| Series A | $200M | Jan 2025 | |
| Series C | $55M | Jan 2025 | |
| Series D | $150M | Dec 2024 | |
| Series A | $140M | Dec 2024 | |
| Series C | $115M | Oct 2024 | |
| Series A | — | Oct 2024 | |
| Series B | $175M | Sep 2024 | |
| Series A | $27M | Sep 2024 | |
| Series C | $106.6M | May 2024 | |
| Unknown | — | Oct 2023 | |
| Series A | $200M | Jan 2023 | |
| Series B | $149M | Dec 2022 | |
| Series B | $118M | Jun 2022 | |
| PPrometheus Biosciences | Unknown | $500M | Jan 2022 |
| Series B | $149M | Jan 2022 | |
| Series B | $70M | Sep 2021 | |
| Series B | $51M | Sep 2021 | |
| Series C | $153M | Jul 2021 | |
| AArtios Pharma Limited | Series C | $153M | Jul 2021 |
Top Co-Investors
Last updated: 7 October 2026